Dept. of Clinical Pharmacology
The Department of Clinical Pharmacology at ACTREC was established with the singular focus of filling the existing gaps in cancer therapeutics in India. The department founded by Dr. Vikram Gota set its roots in July 2008 under the patronage of the prestigious Tata Memorial Centre at the newly built Advanced Centre for Treatment, Research, and Education in Cancer(ACTREC) in Kharghar.
About ACTREC
The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer.
Mission Statement
To excel in personalized therapy and drug development in oncology achieved through translational research conducted in a state-of-the-art environment involving or in collaboration with world leaders in the field.
Vision - 2020
“To improve overall outcomes and provide affordable healthcare in oncology specially to the poor sections of India in cancer through innovative research and education, as we move towards our goal of being a world-class centre in clinical pharmacology and translational medicine .“
Dr. Vikram Gota
Phase 1 Trial Unit
Established to give impetus to early clinical development of anticancer and adjuvant drugs.
Read MoreBio Analytical Research
Research with an aim to provide the tools for chemoprevention, early diagnosis, prognosis and therapy.
Read MoreClinical Research Centre [CRC]
The Clinical Research Centre (CRC), which has been envisaged as a ‘model centre for clinical research’.
Read MoreOur Research Projects
Testimonials
The clinical Pharmacology department at ACTREC led by Dr Vikram has played a crucial supplementary role to the medical oncology patient services and research at Tata Memorial Centre since its inception. Our past and ongoing research projects aim to add value to patient treatment by providing access to quality generics, refining dosage regimens in patients not responding to conventional doses of chemotherapy drugs and aiding the clinical development of newer molecules through the conduct of early phase studies. In addition, the availability of basic research expertise at the department has allowed the bedside to bench translation of oncology drugs. Our collaboration has also lead to establishment of Phase 1 unit at ACTREC. We hope that our association will ring in excellence in the areas of clinical research and cancer treatment services at the institution.